Lupin moves up on receiving USFDA’s nod for generic Tamiflu Capsules

Lupin Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500257 | NSE: LUPIN

10 Jan 2018 Evaluate

Lupin is currently trading at Rs. 928.35, up by 7.50 points or 0.81% from its previous closing of Rs. 920.85 on the BSE.

The scrip opened at Rs. 923.00 and has touched a high and low of Rs. 932.40 and Rs. 915.55 respectively. So far 183017 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1572.25 on 06-Feb-2017 and a 52 week low of Rs. 807.00 on 06-Dec-2017.

Last one week high and low of the scrip stood at Rs. 932.40 and Rs. 870.10 respectively. The current market cap of the company is Rs. 42119.93 crore.

The promoters holding in the company stood at 47.02%, while Institutions and Non-Institutions held 37.64% and 15.35% respectively.

Lupin has received final approval for its Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) from the United States Food and Drug Administration (USFDA) to market a generic version of Hoffman-La Roche, Inc.'s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg.

Lupin's Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are the AB rated generic equivalent of Hoffman-La Roche, Inc.'s Tamiflu Capsules, 30 mg, 45 mg, and 75 mg. Oseltamivir Phosphate Capsules USP, 30 mg (base), 45 mg (base), and 75 mg (base) are indicated for the treatment of acute, uncomplicated influenza A and B in patients 2 weeks of age and older who have been symptomatic for no more than 48 hours, and prophylaxis of influenza A and B in patients 1 year and older.

Oseltamivir Phosphate Capsules USP, 30 mg, 45 mg, and 75 mg had annual sales of approximately $467.8 million in the US, as per IMS MAT October 2017.

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.